Ed­i­tas re­ports ear­ly-stage da­ta from two pa­tients in sick­le cell dis­ease

One com­pa­ny is mov­ing for­ward in its bid to make a cell ther­a­py for sick­le cell dis­ease vi­able — and af­ter pre­vi­ous set­backs, in­clud­ing a hold ear­li­er this year, ex­ecs are tout­ing some re­al­ly ear­ly da­ta.

Ed­i­tas Med­i­cine an­nounced Tues­day morn­ing that it had pos­i­tive safe­ty and ef­fi­ca­cy da­ta from two pa­tients in a Phase I/II tri­al in­ves­ti­gat­ing ED­IT-301, a cell ther­a­py can­di­date that Ed­i­tas de­vel­oped. Safe­ty was mea­sured in both pa­tients, and ef­fi­ca­cy da­ta are from on­ly the first pa­tient dosed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER